Y-Intercept (HK)
DSGN icon

Y-Intercept (HK)’s Design Therapeutics DSGN Stock Holding History

Y-Intercept (HK)’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$408K Buy
32,468
+19,558
+151% +$270K 0.01% 1344
2026
Q2 		$187K Buy
+12,910
New +$161K ﹤0.01% 1580

Other funds holding DSGN

China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Y-Intercept (HK)'s DSGN Position: Q3 2026 in Review

Y-Intercept (HK) increased its Design Therapeutics (DSGN) stake by 151% in Q3 2026, buying an estimated $270K and bringing the position to 32,468 shares worth $408K. The position accounts for 0.01% of the portfolio, ranked #1344.

Y-Intercept (HK) first reported a position in DSGN in Q2 2026 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • Y-Intercept (HK) held 32,468 shares of Design Therapeutics worth $408K as of Q3 2026.
  • Y-Intercept (HK) bought 19,558 Design Therapeutics shares in Q3 2026, an estimated $270K.
  • Design Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1344 holding.
  • Y-Intercept (HK) first reported a position in Design Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.